Please assess the completion status of the following clinical trial:

Trial Title: Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients receiving Tofacitinib (Xeljanz)~Exclusion Criteria:~Not Applicable

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tofacitinib (Xeljanz) (Type: None): Tablets 5 mg BID
- Standard of Care (Type: None): Standard of Care for Rheumatoid Arthritis

Based on this trial design, predict the completion outcome and termination type (if applicable).